TTrialPathMatch Me to Trials
← Back to trials
RecruitingGVHD,Acute

CXCL9 and EASIX for Prediction of Acute Graft Versus Host Disease

Eligible age

18–80 yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The prediction of severe acute GVHD before it occurs is of high importance for ensuing clinical decisions and overall success of allogeneic SCT. The key immunologic signatures associated with clinical outcomes after different graft versus host disease prophylaxis methods or peripheral blood stem cell transplant are largely unknown.

Sponsor: Henry Ford Health System

You may qualify if…

  • Patients \>18 year old admitted for allo SCT PB for malignant disease.

Where it's recruiting

Michigan

Detroit

Source: ClinicalTrials.gov · NCT05718791 · last updated 2026-05-01

CXCL9 and EASIX for Prediction of Acute Graft Versus Host Disease · TrialPath